2-chloro-5-(4-chloro-6-quinolinyl)-N,N-dimethyl-3-pyridinamine | 1201842-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-5-(4-chloro-6-quinolinyl)-N,N-dimethyl-3-pyridinamine
• 英文别名: 2-chloro-5-(4-chloroquinolin-6-yl)-N,N-dimethylpyridin-3-amine
• CAS: 1201842-78-5
• 化学式: C₁₆H₁₃Cl₂N₃
• 分子量: 318.205
• InChiKey: AQEMMIJJTGVJPX-UHFFFAOYSA-N

物化性质

• 沸点：
  475.1±45.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(4-chloro-6-quinolinyl)-N,N-dimethyl-3-pyridinamine 、 1-(1-苯基乙基)哌嗪 在 水 、 乙酸乙酯 、 氯化钠 、 Sodium sulfate-III 、 crude product 、 丙酮 、 hexanes 作用下， 以 二甲基亚砜 为溶剂， 反应 21.5h， 以to afford the title compound as a white solid (0.0886 g)的产率得到2-chloro-N,N-dimethyl-5-(4-(4-(1-phenylethyl)-1-piperazinyl)-6-quinolinyl)-3-pyridinamine
  参考文献：
  名称：

  Inhibitors of PI3 kinase

  摘要：

  本发明涉及公式（I）的化合物或其药学上可接受的盐；使用这些化合物治疗癌症等疾病或病况的方法；以及含有这些化合物的制药组合物，其中Q、X1、X2、R1和Z的定义如本文所述。

  公开号：

  US08415376B2
• 作为产物：
  描述：

  (5-bromo-2-chloro-pyridin-3-yl)-dimethyl-amine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-chloro-5-(4-chloro-6-quinolinyl)-N,N-dimethyl-3-pyridinamine
  参考文献：
  名称：

  [EN] INHIBITORS OF PI3 KINASE
  [FR] INHIBITEURS DE LA PI3 KINASE

  摘要：

  公开号：

  WO2009155121A3

文献信息

• INHIBITORS OF PI3 KINASE
  申请人：Bo Yunxin Y.

  公开号：US20110092504A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X 1 , X 2 , R 1 and Z are as defined herein.

  本发明涉及式（I）的化合物，或其药学上可接受的盐；使用该化合物治疗疾病或病症的方法，例如癌症；以及含有该化合物的制药组合物，其中Q、X1、X2、R1和Z的定义如本文所述。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF
  申请人：UPDATE PHARMA INC.

  公开号：US20160166546A1

  公开（公告）日：2016-06-16

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
• COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF
  申请人：GARNER William J.

  公开号：US20160220537A1

  公开（公告）日：2016-08-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.